1.Uterine clear cell carcinoma risk in White versus non-White US subpopulations: does race matter?
Stephanie CHOW ; Deanna WONG ; Cheng-I LIAO ; Amandeep MANN ; Chunqiao TIAN ; Kathleen M. DARCY ; John K. CHAN
Journal of Gynecologic Oncology 2020;31(6):e81-
Objective:
To determine incidence rates of uterine clear cell carcinoma among non-White US subpopulations.
Methods:
Data from the United States Cancer Statistics and National Cancer Database from 2004 to 2016 were analyzed using descriptive statistics.
Results:
A total of 488,811 women were diagnosed with uterine cancer from 2004–2016.Of these, 73.3% were endometrioid, 6.6% were serous, 5.3% were carcinosarcoma, 1.4% were clear cell, and 13.4% were other. Blacks had the highest incidence rate of uterine clear cell compared with Whites, Asian/Pacific Islanders, and American Indian/Alaska Natives (0.59 vs. 0.31, 0.29, and 0.24, respectively). Overall mean age at diagnosis was 68.6 years, with the youngest age in Asian/Pacific Islanders compared to Whites, Blacks, and American Indian/Alaska Natives (65.9 vs. 68.7, 68.6, and 66.3 years, respectively). Analysis of the Asian subpopulation revealed significantly younger age at diagnosis in Vietnamese women (55.8 years) compared with 72.4 years in Japanese, 68.6 years in Pacific Islander, 66.6 years in Indian/Pakistani, 65.9 years in Filipino, 65.8 years in Chinese, 65.2 years in Korean, and 63.7 years in other Asians.
Conclusions
Black women are two times more likely to be diagnosed with uterine clear cell carcinoma compared with other races. Asians present at younger ages, with Vietnamese women most likely to be diagnosed at the youngest age.
2.Prevalence of perceived weight-based stigmatisation in a multiethnic Asian population.
Koy Min CHUE ; Mang Yik FOO ; Cheryl Min En CHUA ; Bin Chet TOH ; Lester Wei Lin ONG ; Chin Hong LIM ; Jeremy Tian Hui TAN ; Marvin Wei Jie CHUA ; Wai Ching Deanna LEE ; Wai Keong WONG ; Baldwin Po Man YEUNG
Annals of the Academy of Medicine, Singapore 2022;51(9):583-585
3.Therapeutic plasma exchange as a treatment for Central Pontine Myelinolysis in a 41-year-Old male with Chronic Renal Insufficiency: A case report
Guillermo III Lacuesta Manalo ; Aurelio Pantaleon S Reyes ; Jane Wendolyn Wong Lu-Reyes ; Catherine Matnao Carabbacan ; Joice Bumanglag Dela Cruz ; Marie Joyce Urnos Santos ; Donaryn Villa Pasamonte ; Sheryll Juan Pascual ; Deanna Dauz Quilala
Philippine Journal of Internal Medicine 2022;60(3):215-218
Therapeutic plasma exchange (TPE) has been reported as a possible treatment for osmotic demyelination syndrome – central pontine myelinolysis (ODS-CPM), a degeneration of myelin within the central nervous system related to rapid hyponatremia correction, which though uncommon, has significant morbidity, and has no established specific treatment. We present our experience with a 41-year-old male with chronic kidney disease, maintained on steroids, who presented with lethargy and behavioral changes. Initial metabolic panel showed severe hyponatremia (Na 109 mEq/L). Despite cautious sodium correction, the patient’s sensorium decreased further and was intubated. Involuntary movements of the left face and arm were later seen. T2/FLAIR hyperintensities in the brainstem and thalami affirmed the diagnosis of ODS. A total of nine cycles (one cycle every two to three days) of TPE were completed. The patient was discharged with improved sensorium, from E2VxM4 to E4VxM6, and with no indication for hemodialysis due to improved creatinine. One year later, the patient has no remaining neurologic deficits. Our experience supports other case reports that TPE is a viable therapy for ODS-CPM.
Myelinolysis, Central Pontine
;
Renal Insufficiency, Chronic